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• Cell Culture: MDA-MB-231, BT-549, and MCF-7 cells were
obtained from ATCC. Cells were cultured as directed by the
manufacturer guidelines.
• Western Blot: 30 µg of protein was loaded on a 8%
SDS-PAGE and transferred to a nitrocellulose membrane.
Membranes were incubated with primary (CST) and Goat
anti-rabbit 680 LT and Goat anti-mouse 800 CW secondary
antibodies. Membranes were scanned on an Odyssey
Infrared Imager (LI-COR Biosciences) and analyzed using
Image Studio Lite Software.
• MTT Assay: MDA-MB-231 cells were plated at a density of
5x103 cells per well in 96 well plates. MTT was added to
each well and were incubated for 3 hours. Absorbance was
measured at 570 nm using VICTOR3 1420 multi-label
counter, Perkin Elmer).
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Methods
Conclusion
• E-cadherin may be an effective biomarker
to predict response to MEK1/2 pathway
inhibition.
• Constitutive activation of the AKT pathway in
BT-549 cells may be the reason for reduced
efficacy of kinase inhibitors on MET.
Future directions
• Evaluate mechanism of synergy between
kinase inhibitors and doxorubicin.
• Evaluate the effect of MEK1/2 and MEK5
pathway inhibitors in combination with
CDK4/6 inhibitors on cell proliferation.
Hypothesis
MAPK inhibition will induce MET and sensitize triple
negative breast cancer cells to doxorubicin.
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• Extracellular signal-regulated kinase (ERK) 5, a
member of mitogen activated protein kinase
(MAPK) family, is an emerging target in cancer
therapeutics. Activation of ERK5 via
overexpression induces EMT and hormone-
independent growth of breast cancer. EMT leads
to the loss of cell polarity, downregulation of E-
cadherin, and upregulation of mesenchymal
markers snail, zinc-finger E-box binding
homeobox (ZEB1), and vimentin. EMT is also
associated with drug resistance. Although ERK1/2
and ERK5 activation is known to mediate EMT,
the effect of ERK1/2 and ERK5 inhibition on
mesenchymal to epithelial transition (MET), the
reverse of EMT, is poorly understood in cancer.
• Triple negative breast cancer (TNBC) cells have a
mesenchymal phenotype and show poor
sensitivity to chemotherapy agents. The loss of
ER, PR, and HER2 contributes to the aggressive
state of the disease and lack of targeted therapy.
Activation of the intracellular signaling pathways
such as the MAPK pathway mediates
tumorigenesis in TNBCs.
• In the present study, the effect of dual ERK1/2 and
ERK5 inhibition on MET, cell viability, migration,
and anchorage-independent growth was
evaluated in TNBC. ERK1/2 and ERK5 activities
were modulated via pharmacological inhibitors
and molecular tools. Cell morphology and protein
expression of EMT markers E-cadherin and ZEB1
were evaluated. XMD8-92, an ERK5 inhibitor was
found to synergize with doxorubicin in lung cancer.
Therefore, the effect of ERK1/2 and ERK5
inhibition on doxorubicin sensitivity was evaluated.
MEK1/2 and MEK5 mediate ERK5 activation and EMT in MDA-MB-231 cells
ERK5 and ERK1/2 inhibition decreases cell migration, spheroid formation, and 
enhances doxorubicin sensitivity in TNBC cells
Pharmacological inhibition of ERK5 and ERK1/2 induces MET in breast cancer
MDA-MB-231 BT-549
Data represent ± SEM of three different experiments *p<0.05; **p<0.01; ****p<0.0001 vs DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test.
Summary
• ERK1/2 and ERK5 inhibition induces MET in
MDA-MB-231 cells.
• XMD8-92 induces MET in MDA-MB-231
cells via downregulation of ZEB1.
• Trametinib induces MET via inhibition of
ERK1/2-RSK signaling in BT-549 and TAMR-
MCF-7 cells.
• Trametinib and XMD8-92 decrease spheroid
formation and cell migration in TNBC cells.
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Data represent ± SEM of three independent experiments *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group determined by one-way ANOVA and two-way ANOVA with the Bonferroni post hoc test.
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Effects in TAMR MCF-7 cells were similar to BT-549 cells
Effects in TAMR MCF-7 cells were similar to BT-549 cells
Data represent ± SEM of three different experiments *p<0.05; **p<0.01; ****p<0.0001 vs DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test.
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